Patrick J Ward MD PhD

Oncology•Cincinnati, OH

Physician

Join to View Full Profile

4350 Malsbary RdCincinnati, OH 45242
Phone+1 513-751-2273
Fax+1 513-792-5844

Summary

I am a board certified medical oncologist specializing in solid tumor oncology. I am a clinical investigator specializing in cellular therapies for solid tumors. I am the director of clinical research for OHC.

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2000 - 2002
Ohio State University HospitalResidency, Internal Medicine, 1997 - 2000
Ohio State University College of MedicineClass of 1997

Certifications & Licensure

OH State Medical License 1998 - 2025
KY State Medical License 2003 - 2020
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Top MD Consumers Checkbook

Clinical Trials

Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Start of enrollment: 2005 Mar 01
Completed
Not Applicable
A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. Start of enrollment: 2013 Feb 26
Completed
Phase 2
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer Start of enrollment: 2013 Dec 17
COMPLETED
PHASE3
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread Start of enrollment: 2014 Jun 10
Completed
Phase 2
MYLUNG Consortium Part 3: Observational Study Start of enrollment: 2023 Jan 30
RECRUITING
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer Start of enrollment: 2022 Oct 04
RECRUITING
PHASE3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63) Start of enrollment: 2022 Dec 12
RECRUITING
PHASE3
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2022 Oct 12
ACTIVE_NOT_RECRUITING
PHASE3
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects Start of enrollment: 2022 Aug 11
RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
R C Coombes, Sacha Howell, Simon R Lord, Laura Kenny, Janine Mansi
Nature Communications. 2025-03-06
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.
Sylvia M Lee, Omid Hamid, Robert Jotte, Yousef Zakharia, Theresa Medina
Clinical Cancer Research. 2025-03-03
1 citations
Integration of Genetic Testing and Counseling in Patients With Breast Cancer in a Large, Multisite Community-Based Practice.
Molly A Mendenhall, Andrew Guinigundo, Dan Davies, Patrick Ward, David R Drosick
JCO Oncology Practice. 2024-02-01

Press Mentions

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01February 15th, 2024

Professional Memberships

American Society of Clinical Oncology - ASCO
Member